Background Novel Coronavirus disease 2019 or COVID-19 has become a threat to human society due to fast spreading and increasing mortality. It uses vertebrate hosts and presently deploys humans. Life cycle and pathogenicity of SARS-CoV-2 have already been deciphered and possible drug target trials are on the way. Results The present study was aimed to analyze Non-Structural Proteins that include conserved enzymes of SARS-CoV-2 like papain-like protease, main protease, Replicase, RNA-dependent RNA polymerase, methyltransferase, helicase, exoribonuclease and endoribonucleaseas targets to all known drugs. A bioinformatic based web server Drug ReposeER predicted several drug binding motifs in these analyzed proteins. Results revealed that anti-viral drugs Darunavir,Amprenavir, Rimantadine and Saquinavir were the most potent to have 3D-drug binding motifs that were closely associated with the active sites of the SARS-CoV-2 enzymes . Conclusions Repurposing of the antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir to treat COVID-19 patients could be useful that can potentially prevent human mortality. Graphic abstract Supplementary Information The online version contains supplementary material available at 10.1186/s40709-021-00149-2.
【저자키워드】 COVID-19, SARS-CoV-2, antiviral drugs, non-structural proteins, Enzymes, darunavir, Amprenavir, saquinavir, Rimantadine, 【초록키워드】 Coronavirus disease 2019, Mortality, Trial, drugs, repurposing, Proteins, drug, protease, antiviral drug, Helicase, Papain-like protease, humans, methyltransferase, drug target, RNA-dependent RNA polymerase, target, novel, pathogenicity, anti-viral drug, binding, COVID-19 patient, life cycle, active site, Abstract, supplementary material, enzyme, treat, motif, replicase, Host, Prevent, Result, predicted, analyzed, conserved, include, the SARS-CoV-2, 【제목키워드】 antiviral drug, Protein, neutralize, conserved,